## **Core Concept**
The patient presents with symptoms and laboratory findings suggestive of **Rheumatoid Arthritis (RA)**, a chronic autoimmune disorder characterized by symmetrical polyarthritis, particularly affecting small joints. The diagnosis of RA is supported by the presence of **rheumatoid factor (RF)**, **anti-cyclic citrullinated peptide (anti-CCP) antibodies**, and elevated **erythrocyte sedimentation rate (ESR)**.

## **Why the Correct Answer is Right**
The patient's clinical presentation of symmetrical small joint polyarthritis for 2 weeks, along with a high titer of rheumatoid factor (1:320) and strongly positive anti-CCP (58 units), strongly supports the diagnosis of RA. The absence of antinuclear antibodies (ANA) helps to differentiate RA from other autoimmune diseases like **Systemic Lupus Erythematosus (SLE)**. The presence of IgG antibodies to cytomegalovirus and parvovirus indicates past exposure but does not influence the management of RA. Given the diagnosis of RA and the patient's elevated inflammatory markers (ESR of 62 mm/hour), the appropriate next step is to initiate **disease-modifying antirheumatic drugs (DMARDs)**, with **methotrexate** being a common first-line choice.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although **corticosteroids** may be used for symptomatic relief in RA, especially during flares, they are not considered the primary next step in management without concomitant initiation of DMARDs.
- **Option B:** This option is incorrect as there is no clear indication for **biologic agents** as the first-line treatment for RA; they are typically considered if the patient fails to respond to DMARDs.
- **Option C:** This option is incorrect because, while **physical therapy** and **lifestyle modifications** are important components of RA management, they do not address the immediate need to modify the disease process pharmacologically.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that early initiation of DMARDs, such as **methotrexate**, in patients with RA can significantly improve outcomes by slowing disease progression and reducing joint damage. The presence of RF and anti-CCP antibodies not only supports the diagnosis but also often correlates with a more aggressive disease course.

## **Correct Answer:** D. Initiate methotrexate.